| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e238ea0cacfaa0bd0e58c11c23b06683
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a80a5a063f19fb17f5de3a7ed0198679
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32d0469bf177e891e5bdf493aaec5590
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec0472de299a754beb0329657d3873bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_114e4423ec77cbc8dab9d0a98909704e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J41-0016 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
| filingDate |
2008-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec9d4ded241819cac78171a532df1aed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_446558b195fd91cad1bef8b65abab63c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b13e6be346a0f288ea71a5faaee65ae8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7d895a8ac4f60c682a8534af3bc8366 |
| publicationDate |
2009-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009027994-A2 |
| titleOfInvention |
NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3β-OL |
| abstract |
The present invention relates to steroidal esters of 17-oximino -5-androsten-3-ol,of compound of general formula (A) wherein R is selected form a group consisting of arylalkyl, aryl, substituted aryl. The ester derivatives are synthesized starting from Dehydroandrosterone acetate. The compounds were tested for their antiproliferative activity and 5α-reductase inhibitory activity in comparison to Finasteride. Decreased androgen level have been found in serum of animal treated with newly synthesized compounds. These compounds have also shown better cytotoxicity in comparison to reference drug Finasteride. Thus such compounds can be useful in treatment of androgen dependent disorder of prostate alone or by synergistic effect they can decrease the size of prostate due to their antiproliferative activity. |
| priorityDate |
2007-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |